<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02507986</url>
  </required_header>
  <id_info>
    <org_study_id>MOBILE-AF</org_study_id>
    <nct_id>NCT02507986</nct_id>
  </id_info>
  <brief_title>Mobile Phones in Cryptogenic Stroke Patients Bringing Single Lead ECGs to Detect Atrial Fibrillation</brief_title>
  <acronym>MOBILE-AF</acronym>
  <official_title>Mobile Phones in Cryptogenic Stroke Patients Bringing Single Lead ECGs to Detect Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Haaglanden Medisch Centrum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groene Hart Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herning Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alrijne Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Reinier de Graaf Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to compare the incidence of detected atrial fibrillation
      (AF) in cryptogenic stroke patients by a single lead ECG device with the incidence of
      detected AF by a 7-Day Holter ECG.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: A standard work-up of stroke patients to identify a cause of stroke consists of
      Computed Tomography (CT), CT angiography of head and neck arteries, transthoracic
      echocardiography, 12-lead 10-seconds electrocardiogram (ECG), blood tests and 24-hour ECG
      monitoring. A stroke is called &quot;cryptogenic&quot; if no cause can be determined after standard
      work-up. Current detection of atrial fibrillation (AF) after stroke is 2.0%. Recent studies
      revealed that prolonged monitoring yields higher percentages of detected AF (12.0%). Devices
      used in these trials suffer from drawbacks. The investigators' hypothesis is that a new,
      smartphone compatible device, producing a single lead ECG (single lead ECG device), can be
      used for prolonged ECG monitoring in cryptogenic stroke patients.

      Objective: The main objective of this study is to compare the incidence of detected AF in
      cryptogenic stroke patients by a single lead ECG device with the incidence of detected AF by
      a 7-Day Holter ECG.

      Study design: A multicenter randomized trial. Study population: Cryptogenic stroke patients
      admitted to a hospital participating in the study. The calculated sample size is 200 (100 per
      arm).

      Intervention: After inclusion, patients will be randomized to either a single lead ECG device
      or a 7-Day Holter Monitor.

      Main study parameters/endpoints: The main endpoint will be the percentage of detected atrial
      fibrillation in both the single lead ECG device group and the 7-Day Holter group after one
      year.

      Nature and extent of the burden and risks associated with participation, benefit and group
      relatedness: Both devices are battery powered and electrically safe. Patients face a 2-3%
      risk that AF is detected false-positively; this might lead to incorrect oral anticoagulation
      (OAC) prescription. However, a potential benefit of the investigators' study is that if AF is
      detected and treated with OAC, this significantly reduces the chance of recurrent stroke.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of detected atrial fibrillation</measure>
    <time_frame>1 year of follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pro-Brain Natriuretic Peptide (Pro-BNP) levels in pg/mL</measure>
    <time_frame>24 hours after cryptogenic stroke</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of atrial ectopy detected on 7-Day Holter monitor</measure>
    <time_frame>7 days after cryptogenic stroke</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left atrial diameter in cm/m2</measure>
    <time_frame>24 hours after cryptogenic stroke</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a recurrent stroke or TIA as defined in the trial</measure>
    <time_frame>Within one year after cryptogenic stroke</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a major bleeding</measure>
    <time_frame>Within one year after cryptogenic stroke</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left atrial volume in mL/m2</measure>
    <time_frame>24 hours after cryptogenic stroke</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Ischemic Stroke</condition>
  <condition>Transient Ischemic Attack</condition>
  <arm_group>
    <arm_group_label>7-Day Holter monitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive a 7-Day Holter monitor directly after randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single lead ECG device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will be asked to take a single lead ECG two times per day and in case of complaints with a single lead ECG device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Single lead ECG device</intervention_name>
    <description>The single lead ECG device is a smartphone compatible handheld device that produces a single lead ECG after 30 seconds of measurement. It is non-invasive, electrically safe and easy to use.</description>
    <arm_group_label>Single lead ECG device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>7-Day Holter monitor.</intervention_name>
    <description>The Holter is a conventional 7-Day Holter monitor.</description>
    <arm_group_label>7-Day Holter monitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have had an episode of symptomatic Transient ischemic attack (TIA) or
             episode of ischemic stroke.

               -  Ischemic stroke is defined as an episode of transient or neurological dysfunction
                  caused by focal brain or retinal ischemia with recent infarction on imaging

               -  A TIA is defined as transient episode of neurologic dysfunction typically lasting
                  less than one hour caused by focal brain or retinal ischemia without recent
                  infarction on imaging.

        Exclusion Criteria:

          -  Known etiology of TIA or ischemic stroke

          -  TIA or stroke caused by spinal ischemia

          -  TIA only presenting with non-localising symptoms

          -  Uncertainty about the diagnosis of TIA because of unclear clinical symptoms

          -  Myocardial infarction &lt;6 months before stroke

          -  Coronary Artery Bypass Grafting &lt;6 months before stroke

          -  Severe valvular heart disease

          -  Documented history of atrial fibrillation or atrial flutter

          -  Permanent indication for oral anticoagulation at enrolment

          -  Patient has permanent OAC contraindication

          -  Patient is included in another randomized trial

          -  Left ventricular aneurysm on echocardiography

          -  Thrombus on echocardiographyRenal dysfunction (creatinine clearance &lt;30 mL/min/1.73m2)

          -  Patient has life expectancy of &lt;1 year

          -  Patient is not willing to sign the informed consent form

          -  Patient is &lt;18 years of age

          -  Patient is considered an incapacitated adult

          -  Patient is not in possession of a smartphone with Android Operating System (OS) or
             iOS.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serge Trines, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Serge Trines, MD, PhD</last_name>
    <phone>+31 71 526 3928</phone>
    <email>s.a.i.p.trines@lumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regionshospitalet Midtjylland</name>
      <address>
        <city>Herning</city>
        <zip>7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Willem Gielen, MD, PhD</last_name>
      <email>willem@gielen.dk</email>
    </contact>
    <investigator>
      <last_name>Willem Gielen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Hospital</name>
      <address>
        <city>Delft</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E Ronner, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Haaglanden</name>
      <address>
        <city>Den Haag</city>
        <state>Zuid-Holland</state>
        <zip>2512 VA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Grauss, MD, PhD</last_name>
      <email>grauss@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Robert Grauss, MD, PhD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bronovo ziekenhuis</name>
      <address>
        <city>Den Haag</city>
        <state>Zuid-Holland</state>
        <zip>2597 AX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anouk van Alem, MD, PhD</last_name>
      <email>a.vanalem@bronovo.nl</email>
    </contact>
    <investigator>
      <last_name>Anouk van Alem, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suzanne Langerak, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groene Hart Ziekenhuis</name>
      <address>
        <city>Gouda</city>
        <state>Zuid-Holland</state>
        <zip>2803 HH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Reza Alizadeh Dehnavi, MD, PhD</last_name>
      <email>r.alizadeh_dehnavi@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>Reza Alizadeh Dehnavi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serge Trines, MD, PhD</last_name>
      <phone>+31 71 526 3928</phone>
      <email>S.A.I.P.Trines@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>Roderick Treskes, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enno van der Velde, MSc, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marieke Wermer, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Onno Overbeek, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ron Wolterbeek, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin-Jan Schalij, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Serge Trines, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alrijne Hospital</name>
      <address>
        <city>Leiderdorp</city>
        <state>Zuid-Holland</state>
        <zip>2353 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Kirchhof, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2015</study_first_submitted>
  <study_first_submitted_qc>July 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2015</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Serge A. Trines</investigator_full_name>
    <investigator_title>S.A.I.P. Trines, Senior Cardiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

